KEYNOTE-641: Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer

Graff, Julie N.; Liang, Li Wen; Kim, Jeri; Stenzl, Arnulf

dc.contributor.author	Stenzl, Arnulf
dc.date.accessioned	2021-11-30T07:44:13Z
dc.date.available	2021-11-30T07:44:13Z
dc.date.issued	2021
dc.identifier.issn	1744-8301
dc.identifier.uri	http://hdl.handle.net/10900/121098
dc.language.iso	en	de_DE
dc.publisher	Future Medicine Ltd	de_DE
dc.relation.uri	http://dx.doi.org/10.2217/fon-2020-1008	de_DE
dc.subject.ddc	610	de_DE
dc.title	KEYNOTE-641: Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer	de_DE
dc.type	Article	de_DE
utue.quellen.id	20210824232002_01076
utue.publikation.seiten	3017-3026	de_DE
utue.personen.roh	Graff, Julie N.
utue.personen.roh	Liang, Li Wen
utue.personen.roh	Kim, Jeri
utue.personen.roh	Stenzl, Arnulf
dcterms.isPartOf.ZSTitelID	Future Oncology	de_DE
dcterms.isPartOf.ZS-Issue	23	de_DE
dcterms.isPartOf.ZS-Volume	17	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE